Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000844724 | SCV000059870 | pathogenic | Rare genetic deafness | 2016-03-17 | criteria provided, single submitter | clinical testing | The p.Ala2009fs variant in MYO7A has been reported in at least 10 unrelated indi viduals with Usher syndrome including 4 homozygotes and 3 compound heterozygotes , segregated with disease in one family, and was absent from over 400 race-match ed control chromosomes or large population studies (Bharadwaj 2000, Gerber 2006, Jaijo 2007, Jaijo 2009, Maubaret 2005, Najera 2002, Roux 2006, LMM data). This variant is predicted to cause a frameshift, which alters the protein's amino aci d sequence beginning at codon 2009 and leads to a premature stop codon 32 codons downstream. This alteration is then predicted to lead to a truncated or absent protein. In summary, this variant meets our criteria to be classified as pathoge nic for Usher syndrome in an autosomal recessive manner. ACMG/AMP Criteria appli ed: PVS1, PM2, PM3_Very Strong, PP4. |
Labcorp Genetics |
RCV001046525 | SCV001210430 | pathogenic | not provided | 2024-01-04 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ala2009Profs*32) in the MYO7A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYO7A are known to be pathogenic (PMID: 8900236, 25404053). This variant is present in population databases (rs752136791, gnomAD 0.003%). This premature translational stop signal has been observed in individuals with Usher syndrome (PMID: 10930322, 25404053). This variant is also known as Met2018 (1-bp del G). ClinVar contains an entry for this variant (Variation ID: 43313). For these reasons, this variant has been classified as Pathogenic. |
Blueprint Genetics | RCV001075853 | SCV001241492 | pathogenic | Retinal dystrophy | 2019-08-08 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002477080 | SCV002779230 | pathogenic | Autosomal dominant nonsyndromic hearing loss 11; Autosomal recessive nonsyndromic hearing loss 2; Usher syndrome type 1 | 2021-11-09 | criteria provided, single submitter | clinical testing | |
Centre for Genomic Medicine, |
RCV000036218 | SCV000259090 | pathogenic | Usher syndrome type 1 | 2015-01-30 | no assertion criteria provided | clinical testing | |
Counsyl | RCV000036218 | SCV001132253 | pathogenic | Usher syndrome type 1 | 2017-07-07 | no assertion criteria provided | clinical testing | |
Counsyl | RCV000984197 | SCV001132254 | pathogenic | Autosomal recessive nonsyndromic hearing loss 2 | 2017-07-07 | no assertion criteria provided | clinical testing | |
Natera, |
RCV001275528 | SCV001460743 | pathogenic | Usher syndrome type 1B | 2020-09-16 | no assertion criteria provided | clinical testing |